Barron's: Stock buy, dividend hike could boost Pfizer

A big stock buyback or an increased dividend could lift Pfizer shares to $25 over the next year, and the retirement of former CEO Jeff Kindler also gives Pfizer an opportunity to shed assets, Barron's said. Report

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.